Nowadays, the chemotherapy options for the treatment of patients with advanced KRAS mutant microsatellite stable (MSS) CRC are cytotoxic doublets such as FOLFIRI, FOLFOX or FOLFOXIRI in combination with anti-vascular endothelial growth-factor (VEGF) drugs (i.e., bevacizumab and aflibercept) [5]. This evidence concerns the gene VEGFA and colorectal carcinoma.